The protein kinase, GSK-3, participates in diverse biological processes and is now
recognized a promising drug discovery target in treating multiple pathological conditions …

Tardive dyskinesia (TD) is a syndrome of abnormal involuntary movements that follows
treatment with dopamine D2-receptor antagonists. Recent approval of vesicular monoamine …

Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensorimotor
disorder characterized by an urge to move the legs, usually accompanied by or felt to be …

Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that arises as a
complication of exposure to dopamine receptor blocking agents. Vesicular monoamine …

Tardive dyskinesia is a severe motor adverse event of antipsychotic medication,
characterized by involuntary athetoid movements of the trunk, limbs, and/or orofacial areas …

Tardive dyskinesia is a serious, disabling, movement disorder associated with the ongoing
use of antipsychotic medication. Current evidence regarding the pathophysiology of tardive …

Abstract N‐ethoxycarbonyl‐2‐ethoxy‐1, 2‐dihydroquinoline (EEDQ), which irreversibly
inactivates dopamine (DA) receptors, causes pronounced age‐dependent behavioral effects …

Tardive dyskinesia (TD) is a delayed and potentially irreversible motor complication
following chronic exposure to centrally acting dopamine receptor antagonists, mainly of the …

Malgré l'usage de médicaments antipsychotiques depuis plusieurs décennies, leur
mécanisme d'action précis, autre que leur interaction avec les récepteurs dopaminergiques …

Haloperidol (Hal) is an antipsychotic related to movement disorders. Magnesium (Mg)
showed benefits on orofacial dyskinesia (OD), suggesting its involvement with N-methyl-D …